Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as:

• invalidating osteoarthritis / rhumathology / joint health
• skin aging 
• ophthalmology. 

KiOmed’s innovative pipeline is based on a solid building block exclusive technology: KiOmedine®, a medical-grade highly pure natural chitosan-derivative. The patented technology KiOmedine® CM-Chitosan offers competitive advantages thanks to its immune-compatibility and unique structure. Our scientific team has conducted a large number of safety and efficacy studies to demonstrate the unrivaled properties of our KiOmedine®

• Excellent lubrication properties
• Outstanding scavenging capacity
• High ability to protect tissues against oxydative stress

Invalidating OsteoArthritisKioMedine(vs)one is the first soft implant intended to treating OsteoArthritis, an invalidating pathology that affects more than 100 millions of patients worldwide.The unique character of KiOmedine® resides in its innovative chemical design and non-animal origin that allow developing safe medical devices to offer high clinical efficacy thanks to tunable attributes such as lubrication and combating free-radical species.

Related Categories

Sales Markets

Western Europe; Eastern Europe; Asia; North America (USA, Canada); Africa; Central America (e.g. Mexico); Central/South America; East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)